FDA approves oral ganciclovir as first drug to prevent CMV disease. Food and Drug Administration

BETA. 1995 Dec:8.

Abstract

AIDS: The Food and Drug Administration (FDA) has approved oral ganciclovir (Cytovene) to prevent initial episodes of CMV retinitis and other forms of CMV disease among individuals with advanced AIDS (fewer than 100 CD4 cell/mm3). The recommended dosage for primary prophylaxis and maintenance treatment of CMV retinitis is 3,000 mg/day. This dosage would cost around fifty dollars. Cytovene may cause serious bone marrow suppression. Patient profiles should dictate appropriateness of Cytovene use.

Publication types

  • Newspaper Article

MeSH terms

  • AIDS-Related Opportunistic Infections / drug therapy*
  • Administration, Oral
  • Antiviral Agents / administration & dosage
  • Antiviral Agents / therapeutic use*
  • Cytomegalovirus Infections / complications
  • Cytomegalovirus Infections / drug therapy*
  • Cytomegalovirus Retinitis / complications
  • Cytomegalovirus Retinitis / drug therapy*
  • Drug Approval*
  • Drug Costs
  • Ganciclovir / administration & dosage
  • Ganciclovir / therapeutic use*
  • Humans
  • Vereinigte Staaten
  • United States Food and Drug Administration

Substances

  • Antiviral Agents
  • Ganciclovir